Tags

Type your tag names separated by a space and hit enter

Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors.
Am J Ther. 2009 Mar-Apr; 16(2):183-92.AJ

Abstract

The cardiovascular benefits of fish-derived long-chain polyunsaturated fatty acids, docosahexaenoic acid (DHA), and eicosapentaenoic acid are well established. Less studied are specific effects of individual long-chain polyunsaturated fatty acids. Based on data from 16 published clinical trials, this review examines effects of DHA triglyceride (TG) oil derived from algae (algal-DHA) on serum TG levels and related parameters. Study populations included subjects with both normal and elevated TG levels including those with persistent hypertriglyceridemia treated with concomitant 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy. At doses of 1-2 g/d, algal-DHA significantly lowered plasma TG levels (up to 26%) either administered alone or in combination with statins. The reduction in TG levels was markedly greater in hypertriglyceridemic than in normal subjects. Algal-DHA modestly increased plasma levels of both high-density lipoprotein and low-density lipoprotein cholesterol. The increased plasma level of low-density lipoprotein cholesterol was associated with a shift of lipoprotein particle size toward larger, less atherogenic subfractions. In some subjects, blood pressure and heart rate were significantly reduced. Algal-DHA was safe and well tolerated. Unlike fish oil, algal-DHA seldom caused gastrointestinal complaints such as fishy taste and eructation, attributes of importance for patient compliance in high-dose therapy. Regression analysis that showed a linear relationship between baseline TG and magnitude of TG reduction suggests that a study of patients with very high TG levels (>500 mg/dL) is warranted. Future pharmacologic therapies for treating hypertriglyceridemia may include algal-DHA.

Authors+Show Affiliations

Martek Biosciences Corporation, Columbia, MD 21045, USA. alryan@martek.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19145206

Citation

Ryan, Alan S., et al. "Clinical Overview of Algal-docosahexaenoic Acid: Effects On Triglyceride Levels and Other Cardiovascular Risk Factors." American Journal of Therapeutics, vol. 16, no. 2, 2009, pp. 183-92.
Ryan AS, Keske MA, Hoffman JP, et al. Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors. Am J Ther. 2009;16(2):183-92.
Ryan, A. S., Keske, M. A., Hoffman, J. P., & Nelson, E. B. (2009). Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors. American Journal of Therapeutics, 16(2), 183-92. https://doi.org/10.1097/MJT.0b013e31817fe2be
Ryan AS, et al. Clinical Overview of Algal-docosahexaenoic Acid: Effects On Triglyceride Levels and Other Cardiovascular Risk Factors. Am J Ther. 2009 Mar-Apr;16(2):183-92. PubMed PMID: 19145206.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors. AU - Ryan,Alan S, AU - Keske,Michelle A, AU - Hoffman,James P, AU - Nelson,Edward B, PY - 2009/1/16/entrez PY - 2009/1/16/pubmed PY - 2009/5/16/medline SP - 183 EP - 92 JF - American journal of therapeutics JO - Am J Ther VL - 16 IS - 2 N2 - The cardiovascular benefits of fish-derived long-chain polyunsaturated fatty acids, docosahexaenoic acid (DHA), and eicosapentaenoic acid are well established. Less studied are specific effects of individual long-chain polyunsaturated fatty acids. Based on data from 16 published clinical trials, this review examines effects of DHA triglyceride (TG) oil derived from algae (algal-DHA) on serum TG levels and related parameters. Study populations included subjects with both normal and elevated TG levels including those with persistent hypertriglyceridemia treated with concomitant 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy. At doses of 1-2 g/d, algal-DHA significantly lowered plasma TG levels (up to 26%) either administered alone or in combination with statins. The reduction in TG levels was markedly greater in hypertriglyceridemic than in normal subjects. Algal-DHA modestly increased plasma levels of both high-density lipoprotein and low-density lipoprotein cholesterol. The increased plasma level of low-density lipoprotein cholesterol was associated with a shift of lipoprotein particle size toward larger, less atherogenic subfractions. In some subjects, blood pressure and heart rate were significantly reduced. Algal-DHA was safe and well tolerated. Unlike fish oil, algal-DHA seldom caused gastrointestinal complaints such as fishy taste and eructation, attributes of importance for patient compliance in high-dose therapy. Regression analysis that showed a linear relationship between baseline TG and magnitude of TG reduction suggests that a study of patients with very high TG levels (>500 mg/dL) is warranted. Future pharmacologic therapies for treating hypertriglyceridemia may include algal-DHA. SN - 1536-3686 UR - https://www.unboundmedicine.com/medline/citation/19145206/Clinical_overview_of_algal_docosahexaenoic_acid:_effects_on_triglyceride_levels_and_other_cardiovascular_risk_factors_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=19145206.ui DB - PRIME DP - Unbound Medicine ER -